Enhanced antitumor effect of cisplatin in human NSCLC cells by tumor suppressor LKB1

Cancer Gene Therapy

Volumn 19, Issue 7, 2012, Pages 489-498

  Ou, W ^a   Ye, S ^a   Yang, W ^a   Wang, Y ^a   Ma, Q ^a   Yu, C ^a   Shi, H ^a   Yuan, Z ^a   Zhong, G ^a   Ren, J ^a   Zhu, W ^a   Wei, Y ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

cisplatin; combination therapy; LKB1; lung cancer

Indexed keywords

CISPLATIN; GELATINASE A; GELATINASE B; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE LKB1; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GENE THERAPY; CANCER INHIBITION; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; LIFESPAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; FEMALE; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTEIN-SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MAMMALIA; MUS;

EID: 84863721162     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.18     Document Type: Article

References (37)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Keshamouni V, Arenberg D, Kalemkeriam G. Lung Cancer Metastasis Novel Biological Mechanisms and Impact on Clinical Practice. Springer: New York, 2009.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-130.
4. Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin 2011; 61: 91-112.
5. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995; 311: 899-909.
6. Molina JR, Adjei AA, Jett JR. Advances in chemotherapy of non-small cell lung cancer. Chest 2006; 13: 1211-1219. (Pubitemid 44583755)
7. Johnson DH. Evolution of cisplatin-based chemotherapy in non-small cell lung cancer. Chest 2000; 117: 133s-137s.
8. Levine A. Single nucleotide polymorphisms in the p53 pathway. FEBS J 2009; 27: 61-61.
9. Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 2000; 18: 609-622. (Pubitemid 30078542)
10. Ueda K, Kawashima H, Ohtani S, Deng W, Ravoori M, Bankson J et al. The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells. Cancer Res 2006; 66: 9682-9690. (Pubitemid 44623668)
11. Deng WG, Wu G, Ueda K, Xu K, Roth JA, Ji L. Enhancement of antitumor activity of cisplatin in human lung cancer cells by tumor suppressor FUS1. Cancer Gen Ther 2008; 15: 29-39. (Pubitemid 350261296)
12. Makowski L, Hayes DN. Role of LKB1 in lung cancer development. Br J Cancer 2008; 99: 683-688.
13. Shah U, Sharpless NE, Hayes DN. LKB1 and lung cancer: more than the usual suspects. Cancer Res 2008; 68: 3562-3565.
14. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara T, Kozlowski P et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007; 448: 807-810. (Pubitemid 47266337)
15. Koivunen JP, Kim J, Lee J, Rogers AM, Park JO, Zhao X et al. Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. Br J Cancer 2008; 99: 245-252.
16. Gao Y, Ge G, Ji H. LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor suppressor. Protein Cell 2011; 2: 99-107.
17. Carretero J, Shimamura T, Rikova K, Jackson AL, Wilkerson MD, Borgman C et al. Integrative genomic and proteomic analyses identify targets for LKB1-deficient metastatic lung tumours. Cancer Cell 2010; 17: 547-559.
18. Sanchez-Cespedes M, Parrella P, Esteller M, Nomoto S, Trink B, Engles JM et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 2002; 62: 3659-3662. (Pubitemid 34728843)
19. Fan D, Ma C, Zhang H. The molecular mechanisms that underlie the tumor suppressor function of LKB1. Acta Biochim Biophys Sin 2009; 41: 97-107.
20. Vaahtomeri K, Mäkelä TP. Molecular mechanisms of tumor suppression by LKB1. FEBS Lett 2011; 585: 944-951.
21. Chen X, Wang X, Wang Y, Yang L, Hu J, Xiao W et al. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide. J Control Release 2010; 145: 17-25.
22. Yee DS, Tang Y, Li X, Liu Z, Guo Y, Ghaffar S et al. The Wnt inhibitory factor 1 restoration in prostate cancer cells was associated with reduced tumor growth, decreased capacity of cell migration and invasion and a reversal of epithelial to mesenchymal transition. Mol Cancer 2010; 9: 162-175.
23. Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 2000; 6: 1160-1166.
24. Wangpaichitr M, Wu C, You M, Kuo MT, Feun L, Lampidis T et al. Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and antiapoptotic proteins. Eur J Phar 2008; 591: 124-127.
25. Mabuchi S, Kawase C, Altomare DA, Morishige K, Sawada K, Hayashi M et al. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res 2009; 15: 5404-5413.
26. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007; 63: 12-31. (Pubitemid 46810280)
27. Nguyen DM, Spitz FR, Yen N, Cristiano RJ, Roth JA. Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J Thorac Cardiovasc Surg 1996; 112: 1372-1377. (Pubitemid 26403437)
28. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumor suppression. Nat Rev Cancer 2009; 9: 563-575.
29. Cheng H, Liu P, Wang ZC, Zou L, Santiago S, Garbitt V et al. SIK1 couples LKB1 to p53-depengdent anoikis and suppresses metastasis. Sci Signal 2009; 2: 1-11.
30. Lee JH, Koh H, Kim M, Park J, Lee SY, Lee S et al. JNK pathway mediates apoptotic cell death induced by tumor suppressor LKB1 in Drosophila. Cell Death Differ 2006; 13: 1110-1122. (Pubitemid 43905592)
31. Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A et al. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 2000; 288: 870-874. (Pubitemid 30257738)
32. Westermarck J, Kähäri M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999; 13: 781-792. (Pubitemid 29220691)
33. Zeng ZS, Cohen AM, Guillem JG. Loss of basement membrane type Iv collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis 1999; 20: 749-755. (Pubitemid 29191855)
34. Karam AK, Santiskulvong C, Fekete M, Zabih S, Eng C, Dorigo O. Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression. Cytoskeleton (Hoboken) 2010; 67: 535-544.
35. Urso L, Muscella A, Calabriso N, Vetrugno C, Jiménez E, Montiel M et al. Effects of cisplatin on matrix metalloproteinase-2 in transformed thyroid cells. Biochem Pharmacol 2010; 79: 810-816.
36. Upadhyay S, Liu C, Chatterjee A, Hoque MO, Kim MS, Engles J et al. LKB1/STK11 suppresses cyclooxygenase-2 induction and cellular invasion through PEA3 in lung cancer. Cancer Res 2006; 66: 7870-7879. (Pubitemid 44299149)
37. Zhuang ZG, Di GH, Shen ZZ, Ding J, Shao ZM. Enhanced expression of LKB1 in breast cancer cells attenuates angiogenesis, invasion, and metastatic potential. Mol Cancer Res 2006; 66: 7870-7879.